Background <p>Compared with conventional chemotherapy, pembrolizumab-based chemoimmunotherapy (Pembro) and nivolumab plus ipilimumab with or without two cycles of platinum-doublet chemotherapy (Nivo+Ipi) improve survival in advanced non-small cell lung cancer (NSCLC). However, biomarkers for selecting optimal immunotherapy remain unclear. This study aimed to assess whether programmed cell death-ligand 1 (PD-L1) expression on tumor and immune cells (ICs) can guide first-line immunotherapy…
PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC
Journal for ImmunoTherapy of Cancer | | Miyakoshi, J., Yoshida, T., Uehara, Y., Takeyasu, Y., Shirasawa, M., Fukuda, A., Kashima, J., Kumagai, S., Horinouchi, H., Ono, H., Shiraishi, K., Kohno, T., Kondo, S., Goto, Y., Yamamoto, N., Yatabe, Y., Hosomi, Y., Kurata, T., Naoki, K., Suzuki, T., Ohe, Y.
Topics: lung-cancer, blood-cancer, immunotherapy, targeted-therapy, chemotherapy, research
Read the full article at Journal for ImmunoTherapy of Cancer